Literature DB >> 9020496

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.

G Paone1, G De Angelis, L Portalone, S Greco, S Giosué, A Taglienti, A Bisetti, F Ameglio.   

Abstract

By means of a mathematical score previously generated by discriminant analysis on 90 lung cancer patients, a new and larger group of 261 subjects [209 with non-small-cell lung cancer (NSCLC) and 52 with small-cell lung cancer (SCLC)] was analysed to confirm the ability of the method to distinguish between these two types of cancers. The score, which included the serum neuron-specific enolase (NSE) and CYFRA-21.1 levels, permitted correct classification of 93% of the patients. When the misclassifications were analysed in detail, the most frequent errors were associated with limited disease SCLC with low NSE levels and with advanced NSCLC with high NSE levels. This demonstrates the importance of the marker in correctly categorizing patients.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9020496      PMCID： PMC2063371          DOI： 10.1038/bjc.1997.75

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer.

Authors:  M H Gail; L Muenz; K R McIntire; B Radovich; G Braunstein; P R Brown; L Deftos; A Dnistrian; M Dunsmore; R Elashoff
Journal:  J Natl Cancer Inst       Date:  1986-05       Impact factor: 13.506

2.  Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and nonspecific serum markers.

Authors:  F Ameglio; D Giannarelli; P Cordiali-Fei; M Pietravalle; L Alemanno; G Paone; M Amicosante; C Saltini; A Bisetti
Journal:  Am J Clin Pathol       Date:  1994-06       Impact factor: 2.493

3.  Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer.

Authors:  O C Burghuber; B Worofka; G Schernthaner; N Vetter; M Neumann; R Dudczak; R Kuzmits
Journal:  Cancer       Date:  1990-03-15       Impact factor: 6.860

4.  Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.

Authors:  B Wieskopf; C Demangeat; A Purohit; R Stenger; P Gries; H Kreisman; E Quoix
Journal:  Chest       Date:  1995-07       Impact factor: 9.410

5.  Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer.

Authors:  D N Carney; P J Marangos; D C Ihde; P A Bunn; M H Cohen; J D Minna; A F Gazdar
Journal:  Lancet       Date:  1982-03-13       Impact factor: 79.321

6.  Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.

Authors:  N van Zandwijk; E Jassem; J M Bonfrer; W J Mooi; H van Tinteren
Journal:  Semin Oncol       Date:  1992-02       Impact factor: 4.929

7.  Value of serum neuron-specific enolase in nonsmall cell lung cancer.

Authors:  M Diez; A Torres; L Ortega; M Maestro; F Hernando; A Gomez; A Picardo; J Granell; J L Balibrea
Journal:  Oncology       Date:  1993 Mar-Apr       Impact factor: 2.935

8.  Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1.

Authors:  G Paone; G De Angelis; R Munno; G Pallotta; D Bigioni; C Saltini; A Bisetti; F Ameglio
Journal:  Eur Respir J       Date:  1995-07       Impact factor: 16.671

Review 9.  Serum tumour markers in lung cancer: history, biology and clinical applications.

Authors:  D Ferrigno; G Buccheri; A Biggi
Journal:  Eur Respir J       Date:  1994-01       Impact factor: 16.671

10.  Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer.

Authors:  E H Cooper; T A Splinter; D A Brown; M F Muers; M D Peake; S L Pearson
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640
View more
  4 in total

Review 1.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

2.  Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers.

Authors:  Gregorino Paone; Alvaro Leone; Sandro Batzella; Vittoria Conti; Francesco Belli; Laura De Marchis; Alice Mannocci; Giovanni Schmid; Claudio Terzano
Journal:  Inflamm Res       Date:  2012-12-23       Impact factor: 4.575

3.  Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker?

Authors:  Ahmed El Bastawisy; Mahmoud El Azzouny; Gamal Mohammed; Ahmad Awad Allah; Eman Behiry
Journal:  Ecancermedicalscience       Date:  2014-01-30

4.  Plasma lncRNA FEZF1-AS1 as a potential biomarker for diagnosis of non-small-cell lung carcinoma.

Authors:  Yajie Huang; Guangjie Liu; Handie Ma; Yanpeng Tian; Changjie Huang; Fang Liu; Yuxuan Jia; Da Jiang
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.